In addition to CTLA-4– and PD-1/PD-L1–targeted cancer immunotherapy, LAG3 (lymphocyte activation gene-3, CD223) is the third clinically targeted inhibitory receptor (39). This evidence concerns the gene LAG3 and cancer.